Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Pablo Tebas, MD

Pablo Tebas, MD Physician

Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania Director, Developmental Core, Penn Center for AIDS Research Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Tebas is employed by Penn Medicine.

About Dr. Pablo Tebas

Recognized by Best Doctors in America 2007-2008, 2009-2010, 2011-2012

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties


  • Infectious Diseases

Programs & Centers:

Board Certification:

  • Infectious Disease, 2005
  • Internal Medicine, 2004

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Practice Locations and Appointments

  • Penn Infectious Diseases

    Perelman Center for Advanced Medicine South Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School:
Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis


Agence Nationale de Recherche sur le Sida, International American Society for Microbiology (ASM), National Centers for Disease Control, National CLI-107-06 study, International Department of Health and Human Services (DHHS) , National FDA Advisory Committee on Tenofovir , National HIV Medical Association (HIVMA-IDSA), National Infectious Diseases Society of America (IDSA), National International AIDS Society, International International AIDS Society-USA, National National Institutes of Health. ZRG1 AARR1 12 Study Section, National NIH, Division of AIDS, AIDS Clinical Trial Group, National Saint Louis Society of Infectious Diseases, Local Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (Spanish Society of Infectious Diseases and Clinical Microbiology), National Sociedad Española de Medicina Interna (Spanish Society of Internal Medicine), National

Hospital Affiliation

Dr. Tebas is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Selected Publications:

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A: Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Lancet 36 (17): 32299-7,2017.

Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE: Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells Sci Immunol 2 (8): 2017.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ: Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis HIV Med 18 (6): 412-418,2017.

Beigel, J. H., Tebas, P., Elie-Turenne, M. C., Bajwa, E., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J. A., King, K., Burgess, T. H., Aga, E., Lane, H. C., Hughes, M. D., Davey, R. T.: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study Lancet Respir Med 5 (6): 500-511,2017.

Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo: Current use of statins reduces risk of HIV rebound on suppressive HAART PLoS One 12 (3): e0172175,2017.

Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M: A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults J Acquir Immune Defic Syndr 74 (2): 193-200,2017.

O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger J S, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F: A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy Open Forum Infect Dis 4 (1): ofw278,2017.

Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., Learn, G. H., Proschan, M. A., Kreider, E. F., Blazkova, J., Bardsley, M., Refsland, E. W., Messer, M., Clarridge, K. E., Tustin, N. B., Madden, P. J., Oden, K., O'Dell, S. J., Jarocki, B., Shiakolas, A. R., Tressler, R. L., Doria-Rose, N. A., Bailer, R. T., Ledgerwood, J. E., Capparelli, E. V., Lynch, R. M., Graham, B. S.: Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption N Engl J Med 375 (21): 2037-2050,2016.

Post Frank A, Tebas Pablo, Clarke Amanda, Cotte Laurent, Short William, Abram Michael E, Jiang Shuping, Cheng Andrew, Das Moupali: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999) : 2016.

Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD: A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & immunity 1 (1): 154-164,2016.

Academic Contact Info

Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 349-8092
Patient appointments: 800-789-7366 (PENN)

Related Links